This site has been optimized to work with modern browsers and does not fully support your version of Internet Explorer.

What a health innovation network is for, and when to use one

Author

Two months into this job, the question I am asked most often is some version of “so what does the health innovation network (HIN) and Health Innovation Oxford and Thames Valley (HIOTV) do?” It comes from consultants, from ICB colleagues, from company founders and from people who have sat on the same committees as us for years. I have been a clinician involved in innovation for a long time and I ran a Trust innovation programme. I had worked with HIOTV. I still did not have a working answer until I was inside it.

Here is the version I now give.

The NHS has an innovation arm. It is made up of 15 regional organisations, the health innovation networks, set up in 2013 as Academic Health Science Networks and renamed in 2023. They are commissioned by NHS England and the Office for Life Sciences. HIOTV is the one for the Berkshire, Buckinghamshire and Oxfordshire footprint, so around 3 million people and every acute, community and mental health provider in that area.

What does a health innovation network do?

The remit is adoption and spread: helping the NHS take things that already work and get them to patients. The research system discovers things and tests them. Commissioners and providers run services. A gap sits between the two, where something has been shown to work and has still not reached the patients it was built for. Bridging that gap is the HIN’s job.

The HIN has a unique collection of skills and expertise not often found within individual trusts and ICBs. It has health economists who can size a problem and put a value on solving it. It has programme teams that run national adoption work, including the patient safety programmes every provider is expected to deliver. It has a front door for industry, which means smaller companies arrive with their products already triaged rather than landing on a clinical director’s inbox. For larger companies, including pharma, we act as an honest broker. That means we’re a neutral go-between, building partnerships between them and the NHS. And it has the standing to convene across organisations without owning any of them, which turns out to matter more than it sounds.

What are the limits of a health innovation network?

It is worth being clear about what a HIN is not. It does not commission. It does not hold the budget to roll anything out at scale. It cannot make a provider adopt a product. What it can do is take a problem that is stuck and move it: find the evidence, find the money, find the other trust that already solved it, or tell you honestly that the evidence is not there yet.

When should you contact us?

Contact us if you are:

  • a clinician with an idea and no route to test it
  • someone who runs a service with a known problem and suspects someone else has already fixed it
  • in an ICB and need an independent view of whether a technology is worth the money before a decision lands on a committee
  • a company that wants to work with the NHS, from a start-up with a new product to a pharma company seeking a partnership
  • a lead on patient safety with a national programme to deliver and local capacity that does not stretch to it

Each of these is an entry point, leading to a specific team within the HIN.

This is the first of a series of blogs I plan to post over the next few months. Each time I will focus on a different one of these doors: how industry engagement works and why it is gated, how we size a regional problem and what the number is used for, how the patient safety work lands in providers, and where clinical innovators fit in all of this. The aim is that by the end of the series you will know which door is yours, whether you are an ICB director, a ward sister or a founder.

If you cannot wait for my deep dives, get in touch and we’ll help you find the right door.
info@healthinnovationoxford.org

About the author

News Categories: Blog